linjc16/ctgov huggingface dataset:
Shanghai Eye Study for Adults

Study Overview
=================
Brief Summary
-----------------
Blindness and visual impairment severely impact the visual health and life quality of people, particularly the 2.566 million senior citizens aged at 65 and above in Shanghai. The main reason is uncorrected refractive error, of which, 62.1% can be solved through refractive correction. For this reason, the uncorrected refractive errors of 154,000 senior citizens in Shanghai can be taken as a priority among the public health issues to prevent blindness. Now, with the aim to reduce the prevalence rate of blindness and visual impairment, it is planned to establish a public health service mechanism in terms of refractive error screening and correction for the elderly by relying on Shanghai's three-level (city-district-community) eye diseases prevention network, using proper refractive correction technology, and moving related services forward to communities in order to screen, identity, and correct blindness and visual impairment caused by refractive errors as early as possible.

Official Title
-----------------
Shanghai Eye Study for Adults

Conditions
-----------------
Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging

Intervention / Treatment
-----------------
* Device: spectacles


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: shanghai residents aged ≥18 years old Exclusion Criteria: cognitive and/or mobility disorders; non-shanghai residents; younger than 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: corrected refractive error<br> | Device: spectacles<br>* dispending spectacles for uncorrected refractive error<br>|
| No Intervention: uncorrected refractive error<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| best-corrected visual acuity (BCVA) | the prevalence of blindness and visual impairment | 5 years | 
| cataract surgery rate | cataract surgery rate of Shanghai older people | 5 years | 
| cataract surgery coverage rate | cataract surgery coverage rate of Shanghai cataract patients | 5 years | 
| visual impairment caused by high myopia | observing the rate of visual impairment caused by high myopia | 5 years |
Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI

Study Overview
=================
Brief Summary
-----------------
This study aims at evaluating the diagnostic efficacy of Gadobutrol versus Gadobenate dimeglumine at similar dose of 0.1mmol/kg for assessment of myocardial infarction by delayed enhancement cardiac Magnetic Resonance Imaging

Official Title
-----------------
Single Dose Gadobutrol in Comparison to Single Dose Gadobenate Dimeglumine for Magnetic Resonance Imaging of Chronic Myocardial Infarction at 3 Tesla

Conditions
-----------------
Subacute/Chronic Myocardial Infarction

Intervention / Treatment
-----------------
* Other: Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of myocardial infarction Age ≥ 18 years and ≤ 80 years Informed consent Male patients as well as female patients using contraceptives Exclusion Criteria: Patients with a heart pacemaker, with magnetic material or other magnetic implants. Renal failure (GFR <30ml/min) Patients with known allergy to a Gadolinium-containing contrast agent Drugs or alcohol addiction, dementia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gadobutrol<br>first session gadobutrol second session gadobenate dimeglumin | Other: Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)<br>* Other (Diagnostic)<br>|
| Experimental: Demeglumin<br>first session gadobenate dimeglumin second session gadobutrol | Other: Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)<br>* Other (Diagnostic)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy (contrast-to-noise ratio) |  |  |
Investigation of Mortality, Morbidity and Risk Factors After Pediatric Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
The Department of Organ Transplantation in Memorial Hospitals has started Pediatric Liver Transplantation Program in 2016. As of the end of 2020, we have performed 169 pediatric liver transplantation. The aim of this study is to investigate the overall mortality, morbidity and risk factors for adverse outcomes in pediatric liver transplantation. The patients' records will be retrospectively scanned and the data will be gathered.

Official Title
-----------------
Investigation of Mortality, Morbidity and Risk Factors After Pediatric Liver Transplantation: A Retrospective Study

Conditions
-----------------
Liver Transplantation, Liver Diseases, Biliary Atresia, Morbidity;Infant, Mortality

Intervention / Treatment
-----------------
* Procedure: Liver Transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients with liver transplantation (<18 years) Exclusion Criteria: Patients with incomplete medical records will be excluded

Ages Eligible for Study
-----------------
Minimum Age: 0 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Pediatric Patients with Liver Transplantation<br> | Procedure: Liver Transplantation<br>* Liver Transplantation is performed under spesific conditions to increase the life time of patients with liver diseases.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Patient and graft survival ratios | 1 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative informations | Perioperative informations such as blood loss and blood transfusion | 5 minutes | 
| Blood Tests | Blood markers that evaluated at the pre and post operative phase such as Internation Normalized Ratio (INR), total bilirubin and albumin values. | 15 minutes | 
| Postoperative Complications | Postoperative Complications such as sepsis or hepatic artery thrombosis | 5 minutes | 
| Postoperative informations | Postoperative informations such as initial hospital stay, ICU stay or mechanic ventilation time | 10 minutes |
General Anesthesia vs. Local Anesthesia in Stereotaxy

Study Overview
=================
Brief Summary
-----------------
Examination of stress level in general anesthesia in comparison to local anesthesia in stereotactic biopsy

Detailed Description
-----------------
Stereotactic biopsy is routinely performed under local or general anesthesia. The advantage of local anesthesia might be reduction in cardiac and pulmonal complications, reduction of surgical time, and reduction of hospital stay. On the other hand it has been postulated that intraoperative seizures are avoided by general anesthesia and that brain tumor surgery is perceived in the public as psychological and physical stress.Therefor we postulate that patients undergoing stereotactic biopsies in local anesthesia show a higher stress level than patients operated under general anesthesia.

Official Title
-----------------
General Anesthesia vs. Local Anesthesia in Stereotaxy

Conditions
-----------------
Brain Lesion, Stereotactic Biopsy

Intervention / Treatment
-----------------
* Procedure: general anesthesia in stereotactic biopsy
* Procedure: local anesthesia in stereotactic biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: planned stereotactic biopsy age > 18 years Exclusion Criteria: pregnancy anxiety disorder impaired consciousness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Stress level after general anesthesia<br> | Procedure: general anesthesia in stereotactic biopsy<br>* stereotactic biopsy<br>|
| Other: Stress level after local anesthesia<br> | Procedure: local anesthesia in stereotactic biopsy<br>* stereotactic biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PTSS-10 |  | Three days after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stress level, stereotactic biopsy, brain lesion, general anesthesia, local anesthesia
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil

Study Overview
=================
Brief Summary
-----------------
• To describe patients outcomes in terms of overall survival (OS) in locally advanced NSCLC in Brazil

Detailed Description
-----------------
To describe the demographic, clinical and pathological characteristics of patients diagnosed with locally advanced NSCLC; To describe the type of definitive therapy for locally advanced NSCLC To determine progression-free survival (PFS) after definitive therapy To estimate time to next treatment (TNT) after definitive therapy NSCLC in Brazil; To describe the patterns of recurrence/progression and treatment sequencing; To test the association of demographic, clinical and pathological characteristics with PFS, OS To compare the patterns of care (number of hospitalizations; visits to emergency room or ICU; outpatient unit visits) and outcomes between the private and public health care system;

Official Title
-----------------
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil

Conditions
-----------------
Lung Cancer, Non-small Cell

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 years or older Histologically or cytological diagnosis of NSCLC in the period of January 2015 to December 2016 Locally Advanced NSCLC defined as clinical stage IIIA and IIIB according to 7th Edition TNM Staging System Any NSCLC histological subtype and molecular mutation Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis Patients assigned by treating physician to any therapy or palliative care Access to patient medical chart for data collection Exclusion Criteria: Small cell lung cancer and non-invasive NSCLC; Synchronic NSCLC or second primary tumour in the last 5 years (except non-melanoma skin cancer).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | defined as time from diagnosis to death of any cause; | Up to June 30, 2018 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival | defined as time from any line of treatment to progression of the disease or death of any cause | Up to June 30, 2018 | 
| Time to next treatment | defined as time from start of the any treatment to the beginning of a second therapy | Up to June 30, 2018 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung cancer, Non-small cell
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

Study Overview
=================
Brief Summary
-----------------
To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.

Detailed Description
-----------------
Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of enrollment will receive 2 months of study drug and undergo follow-up.

Official Title
-----------------
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

Conditions
-----------------
Cytomegalovirus Retinitis, HIV Infections

Intervention / Treatment
-----------------
* Drug: Ganciclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: AIDS. Stable CMV retinitis. Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days. No permanent central IV catheter at present. Had a permanent central IV catheter removed two or more times within the past 6 months due to catheter infection or thrombosis. Consent of guardian if less than legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Require continuation of concomitant medications precluded by this protocol. Concurrent Medication: Excluded: Intravitreal anti-CMV treatment. Any other concomitant medications precluded by the protocol. Patients with the following prior condition are excluded: History of hypersensitivity to acyclovir or ganciclovir.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ganciclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinitis, Ganciclovir, Administration, Oral, Acquired Immunodeficiency Syndrome
Comparison of the Two Validated German Versions of the Tinnitus Functional Index for Switzerland and for Germany

Study Overview
=================
Brief Summary
-----------------
Tinnitus is defined as a perception of sound without any external sound source. Chronic tinnitus is a frequent condition that can affect the quality of life. The questionnaire Tinnitus Functional Index (TFI) promises to be the new gold standard in tinnitus evaluation. Due to the forward and backward translation of this questionnaire, there are two different German versions of TFI for Switzerland and Germany. Both German versions were validated. The aim of this study is to compare the two German versions of the TFI with each other and to recommend the better one for the further use in tinnitus evaluation for the German speaking population.

Official Title
-----------------
Prospektive Studie Zum Vergleich Der Beiden Validierten Deutschen Versionen Des Tinnitus Functional Index für Die Schweiz Und für Deutschland

Conditions
-----------------
Tinnitus, Subjective

Intervention / Treatment
-----------------
* Other: No intervention planned


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Electronic given informed consent Older than 18 years Existing tinnitus Sufficient knowledge of the German language Exclusion Criteria: Insufficient knowledge of the German language Impossibility to fulfill an online questionnaire due to cognitive or physical limitation No tinnitus Younger than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Swiss version first<br>This group will first complete the Swiss version and second the German version of the TFI | Other: No intervention planned<br>* No Intervention planned.<br>|
| German version first<br>This group will first complete the German version and second the Swiss version of the TFI | Other: No intervention planned<br>* No Intervention planned.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the TFI sumscore of both German versions | TFI sumscore ranges from 0 to 100 | 20 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factor analysis of the two German TFI versions |  | 20 minutes |
Role of Instructions in Nitrous Oxide Effects and Choice - 10

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To evaluate the role of instructions in nitrous oxide subjective effects and choice.

Official Title
-----------------
Role of Instructions in Nitrous Oxide Effects and Choice

Conditions
-----------------
Opioid-Related Disorders, Substance-Related Disorders

Intervention / Treatment
-----------------
* Drug: Nitrous oxide 10% & placebo
* Drug: Nitrous oxide 20% & placebo
* Drug: Nitrous oxide 30% & placebo
* Drug: Nitrous oxide 40% and placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 32 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Informed group<br>Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation. | Drug: Nitrous oxide 10% & placebo<br> <br> Drug: Nitrous oxide 20% & placebo<br> <br> Drug: Nitrous oxide 30% & placebo<br> <br> Drug: Nitrous oxide 40% and placebo<br> <br> |
| Active Comparator: Non-informed Group<br>Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice. | Drug: Nitrous oxide 10% & placebo<br> <br> Drug: Nitrous oxide 20% & placebo<br> <br> Drug: Nitrous oxide 30% & placebo<br> <br> Drug: Nitrous oxide 40% and placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Choice of nitrous oxide vs placebo | Subjects inhaled placebo and varying per centages of nitrous oxide in sampling pair, then chose for third inhalation. One group was told which of the gases they were inhaling during sampling and one group as well as the technician administering the inhalant was blinded. Psychomotor tests were done at each dose. | After 30 min inhalation of each | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nitrous oxide, instruction, subjective effects, reinforcer, healthy volunteer
Type 1 Diabetes Mellitus Effect on Bone Mineral Density

Study Overview
=================
Brief Summary
-----------------
Because the diabetics are fracturing at a younger age than the general population (12), this leads us to believe there are significant factors that lead to fracture in Type 1 diabetes mellitus (DM) other than bone mineral density (BMD). Very little longitudinal data exists on BMD in adults with Type 1 DM and the effects of glucose control on BMD. No longitudinal data exists on pQCT in adults with Type 1 DM. Hypothesis: Adult subjects with diabetes and poor glucose control will lose bone mineral density (BMD) as measured by DXA compared to age and sex matched healthy controls.

Detailed Description
-----------------
Because the diabetics are fracturing at a younger age than the general population(12), this leads us to believe there are significant factors that lead to fracture in Type 1 DM other than BMD. Very little longitudinal data exists on BMD in adults with Type 1 DM and the effects of glucose control on BMD. No longitudinal data exists on pQCT in adults with Type 1 DM. Hypothesis: Adult subjects with diabetes and poor glucose control will lose bone mineral density (BMD) as measured by DXA compared to age and sex matched healthy controls.

Official Title
-----------------
Type 1 DM Effect on BMD: a Longitudinal Study in Adults

Conditions
-----------------
Diabetes Mellitus, Osteoporosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetic patients must have completed Visit 1 of the previous study.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes<br>patients with Type 1 Diabetes Mellitus | |
| Control<br>Age and sex matched control subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone mineral Density | Bone mineral density will be measured yearly for 5 years | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes mellitus, bone